Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Berberine in Treating Negative Symptoms of Schizophrenia
NCT07356765Enrolling by invitation
- Sponsor
- Tianjin Anding Hospital
- Start
- Sep 2023
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of berberine in schizophrenia (2 arms), sponsored by Tianjin Anding Hospital. Primary endpoints: Scale for Assessment of Negative Symptoms at 12 weeks and log50 of the cutaneous niacin flush at 12 weeks. Started Sep 2023; status: enrolling by invitation.
02
Drugs
berberine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT07356765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07356765.